BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 32344066)

  • 1. Validation of a 40-gene expression profile test to predict metastatic risk in localized high-risk cutaneous squamous cell carcinoma.
    Wysong A; Newman JG; Covington KR; Kurley SJ; Ibrahim SF; Farberg AS; Bar A; Cleaver NJ; Somani AK; Panther D; Brodland DG; Zitelli J; Toyohara J; Maher IA; Xia Y; Bibee K; Griego R; Rigel DS; Meldi Plasseraud K; Estrada S; Sholl LM; Johnson C; Cook RW; Schmults CD; Arron ST
    J Am Acad Dermatol; 2021 Feb; 84(2):361-369. PubMed ID: 32344066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced metastatic risk assessment in cutaneous squamous cell carcinoma with the 40-gene expression profile test.
    Ibrahim SF; Kasprzak JM; Hall MA; Fitzgerald AL; Siegel JJ; Kurley SJ; Covington KR; Goldberg MS; Farberg AS; Trotter SC; Reed K; Brodland DG; Koyfman SA; Somani AK; Arron ST; Wysong A
    Future Oncol; 2022 Mar; 18(7):833-847. PubMed ID: 34821148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of a prognostic 40-gene expression profiling test on clinical management decisions for high-risk cutaneous squamous cell carcinoma.
    Litchman GH; Fitzgerald AL; Kurley SJ; Cook RW; Rigel DS
    Curr Med Res Opin; 2020 Aug; 36(8):1295-1300. PubMed ID: 32372702
    [No Abstract]   [Full Text] [Related]  

  • 4. Impact of Gene Expression Profile Testing on the Management of Squamous Cell Carcinoma by Dermatologists.
    Rebeca T; Giselle P; Litchman GH; Rigel DS
    J Drugs Dermatol; 2019 Oct; 18(10):980-984. PubMed ID: 31584775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene expression profiling for metastatic risk in head and neck cutaneous squamous cell carcinoma.
    Arron ST; Wysong A; Hall MA; Bailey CN; Covington KR; Kurley SJ; Goldberg MS; Kasprzak JM; Somani AK; Ibrahim SF; Brodland DG; Cleaver NJ; Maher IA; Xia Y; Koyfman SA; Newman JG
    Laryngoscope Investig Otolaryngol; 2022 Feb; 7(1):135-144. PubMed ID: 35155791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Evidence Shows Clinicians Appropriately Use the Prognostic 40-Gene Expression Profile (40-GEP) Test for High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients.
    Hooper PB; Farberg AS; Fitzgerald AL; Siegel JJ; Rackley BB; Prasai A; Kurley SJ; Goldberg MS; Litchman GH
    Cancer Invest; 2022 Nov; 40(10):911-922. PubMed ID: 36073945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigating proteome changes between primary and metastatic cutaneous squamous cell carcinoma using SWATH mass spectrometry.
    Azimi A; Lo K; Kim J; Fernandez-Penas P
    J Dermatol Sci; 2020 Aug; 99(2):119-127. PubMed ID: 32651104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrating gene expression profiling into NCCN high-risk cutaneous squamous cell carcinoma management recommendations: impact on patient management.
    Farberg AS; Hall MA; Douglas L; Covington KR; Kurley SJ; Cook RW; Dinehart SM
    Curr Med Res Opin; 2020 Aug; 36(8):1301-1307. PubMed ID: 32351136
    [No Abstract]   [Full Text] [Related]  

  • 9. Molecular risk prediction in cutaneous melanoma: A meta-analysis of the 31-gene expression profile prognostic test in 1,479 patients.
    Greenhaw BN; Covington KR; Kurley SJ; Yeniay Y; Cao NA; Plasseraud KM; Cook RW; Hsueh EC; Gastman BR; Wei ML
    J Am Acad Dermatol; 2020 Sep; 83(3):745-753. PubMed ID: 32229276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients.
    Zager JS; Gastman BR; Leachman S; Gonzalez RC; Fleming MD; Ferris LK; Ho J; Miller AR; Cook RW; Covington KR; Meldi-Plasseraud K; Middlebrook B; Kaminester LH; Greisinger A; Estrada SI; Pariser DM; Cranmer LD; Messina JL; Vetto JT; Wayne JD; Delman KA; Lawson DH; Gerami P
    BMC Cancer; 2018 Feb; 18(1):130. PubMed ID: 29402264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcriptomic analysis of cutaneous squamous cell carcinoma reveals a multigene prognostic signature associated with metastasis.
    Wang J; Harwood CA; Bailey E; Bewicke-Copley F; Anene CA; Thomson J; Qamar MJ; Laban R; Nourse C; Schoenherr C; Treanor-Taylor M; Healy E; Lai C; Craig P; Moyes C; Rickaby W; Martin J; Proby C; Inman GJ; Leigh IM
    J Am Acad Dermatol; 2023 Dec; 89(6):1159-1166. PubMed ID: 37586461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validating 4 Staging Systems for Cutaneous Squamous Cell Carcinoma Using Population-Based Data: A Nested Case-Control Study.
    Roscher I; Falk RS; Vos L; Clausen OPF; Helsing P; Gjersvik P; Robsahm TE
    JAMA Dermatol; 2018 Apr; 154(4):428-434. PubMed ID: 29516080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Staging cutaneous squamous cell carcinoma metastases to the parotid gland.
    Czerwonka L; De Santis RJ; Horowitz G; Hong M; Orsini M; Enepekides D; Goldstein DP; Dort J; Higgins K
    Laryngoscope; 2017 Sep; 127(9):2063-2069. PubMed ID: 28295401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Prognostic Value and Clinical Utility of the 40-Gene Expression Profile (40-GEP) Test in Cutaneous Squamous Cell Carcinoma: Systematic Review and Meta-Analysis.
    Masarwy R; Shilo S; Carmel Neiderman NN; Kampel L; Horowitz G; Muhanna N; Mansour J
    Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37173922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of patients at risk of metastasis using a prognostic 31-gene expression profile in subpopulations of melanoma patients with favorable outcomes by standard criteria.
    Gastman BR; Gerami P; Kurley SJ; Cook RW; Leachman S; Vetto JT
    J Am Acad Dermatol; 2019 Jan; 80(1):149-157.e4. PubMed ID: 30081113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective validation of the prognostic 31-gene expression profiling test in primary cutaneous melanoma.
    Keller J; Schwartz TL; Lizalek JM; Chang ES; Patel AD; Hurley MY; Hsueh EC
    Cancer Med; 2019 May; 8(5):2205-2212. PubMed ID: 30950242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TERT promoter mutations are associated with poor prognosis in cutaneous squamous cell carcinoma.
    Campos MA; Macedo S; Fernandes M; Pestana A; Pardal J; Batista R; Vinagre J; Sanches A; Baptista A; Lopes JM; Soares P
    J Am Acad Dermatol; 2019 Mar; 80(3):660-669.e6. PubMed ID: 30165166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrating the 40-Gene Expression Profile (40-GEP) Test Improves Metastatic Risk-Stratification Within Clinically Relevant Subgroups of High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients.
    Wysong A; Somani AK; Ibrahim SF; CaƱueto J; Fitzgerald AL; Siegel JJ; Prasai A; Goldberg MS; Farberg AS; Regula C; Bar A; Kasprzak J; Brodland DG; Koyfman SA; Arron ST
    Dermatol Ther (Heidelb); 2024 Mar; 14(3):593-612. PubMed ID: 38424384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analytical validity of DecisionDx-SCC, a gene expression profile test to identify risk of metastasis in cutaneous squamous cell carcinoma (SCC) patients.
    Borman S; Wilkinson J; Meldi-Sholl L; Johnson C; Carter K; Covington KR; Fitzgerald AL; Kurley SJ; Farberg AS; Goldberg MS; Monzon FA; Oelschlager K; Cook RW
    Diagn Pathol; 2022 Feb; 17(1):32. PubMed ID: 35216597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimation of Prognosis in Invasive Cutaneous Melanoma: An Independent Study of the Accuracy of a Gene Expression Profile Test.
    Greenhaw BN; Zitelli JA; Brodland DG
    Dermatol Surg; 2018 Dec; 44(12):1494-1500. PubMed ID: 29994951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.